Vivalyx secures 5.4 million euros in seed financing

New hope for organ transplants: Vivalyx receives fresh capital to improve donor organ quality

Aachen, April 30, 2024 - The Aachen-based organ vitality tech company Vivalyx GmbH has received an investment of 5.4 million euros in an oversubscribed seed financing round. The investment was led by TechVision Fonds (TVF) and Brightlands Venture Partners (BVP). The team, led by Dr. Andreas Schumacher and Dr. Benedict Doorschodt, is developing solutions to increase organ viability with the aim of increasing the number of organs available for life-saving transplants. The capital raised will be used to fund the necessary clinical trials to obtain regulatory approvals and to begin commercialization.

The financing round brings us a decisive step closer to bringing our products to the market.

Dr. Andreas Schumacher, CEO of Vivalyx.

Shortage of donor organs remains a critical unmet medical need

Patients and doctors are waiting for progress in the field of organ transplantation and the statistics back up the need for it. The average wait time for a donor kidney is up to eight years, and over one million patients worldwide are currently waiting for a donor organ.

This shortage of donor organs can be solved by perfusing organs at body temperature: a clinically proven method, but one that is hardly scalable due to its dependence on rare donor blood and high costs.

Vivalyx introduces a patented solution that overcomes this hurdle for the first time and makes perfusion at body temperature scalable. Their liquid product, Vivalyx Omnisol, outperforms the efficacy of the blood-based benchmark in preclinical studies, is fully synthetic - eliminating blood-related concerns - and significantly reduces costs. Vivalyx Omnisol not only works for body temperature perfusion, but is intended for all methods, cold and warm perfusion as well as static cold storage, with expected favorable clinical outcomes.

International investors and business angels invest in the founding team

We look forward to supporting the dedicated team and the outstanding technology together with this great consortium of investors in the coming years

Bernhard Kugel, Managing Director of TVF

Dr. Andreas Schumacher and Dr. Benedict Doorschodt founded Vivalyx 2022 together with co-founders Prof. Dr. René Tolba, Dr. Christian Bleilevens, Prof. Dr. Malte Brettel and Marius Rosenberg. The product idea is based on decades of research by Doorschodt, Tolba and Bleilevens. Overall, the team combines entrepreneurial experience with in-depth knowledge of organ transplants. In addition to the lead investors, the experienced founding team succeeded in attracting other industry experts such as Arve Capital, the US deeptech VC Goose Capital and other well-known business angels such as Springboard Health Angels, Andrej Henkler and Thomas Ebeling, former CEO of Novartis Pharma.